Immunic’s Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

All NewsApril 17, 2026

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.

Latest Ratings for IMUX

DateFirmActionFromTo Sep 2021HC Wainwright & Co.MaintainsBuy Apr 2021Aegis CapitalInitiates Coverage OnBuy Mar 2021JMP SecuritiesInitiates Coverage OnMarket Outperform

View More Analyst Ratings for IMUX

View the Latest Analyst Ratings

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent